Search
Isatin
go.drugbank.com/drugs/DB02095ExperimentalIsatin is an indole derivative first obtained by Erdman and Laurent in 1841 as an oxidation product of Indigo dye with nitric acid and chromic acids.
LS11
go.drugbank.com/drugs/DB05918InvestigationalIt is used to treat many kinds of cancers. … LS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity.
AMP-201
go.drugbank.com/drugs/DB18663ExperimentalAMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.
NRP369
go.drugbank.com/drugs/DB06384ExperimentalNRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].
Corticosterone
go.drugbank.com/drugs/DB04652InvestigationalAn adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.
Mesterolone
go.drugbank.com/drugs/DB13587InvestigationalIt is inactivated by 3α-hydroxysteroid dehydrogenase in skeleta muscules so it is considered a weak androgen. It is not a substrate for aromatase so it is not converted into estrogen. … Experiments of mesterolone serving as a potential treatment of depression are still undergoing.
AEM-28
go.drugbank.com/drugs/DB17642InvestigationalAEM-28 is a 28 amino acid mimetic of apolipoprotein E being investigated for lipid disorders, such as homozygous familial hypercholesterolemia. It possesses anti-inflammatory properties.[A258764]
WP-1301
go.drugbank.com/drugs/DB17702ExperimentalWP1301 is a synthetic peptide derived from hFVIII. It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]
Abetimus
go.drugbank.com/drugs/DB06662InvestigationalAbetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.
Pelitinib
go.drugbank.com/drugs/DB05524InvestigationalPelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.